Bone Abstracts

The purpose of this presentation is to present the guidelines for recommending surgery for asymptomatic primary hyperparathyroidism, based on a workshop held in 2013. The indications for surgery were: i) a serum calcium more than 1 mg/dl (or 0.25 mmol/l) above the reference interval; ii) a low bone density (T-score −2.5 or less at the lumbar spine, total hip, femoral neck, or distal radius 1/3) or presence of vertebral fracture; iii) chronic kidney disease stage...

Abstract unavailable....

Glucocorticoids inhibit osteoblast function and cause an increase in osteoblast and osteocyte apoptosis. Bone remodelling defects occur resulting in an increase in fracture risk that cannot be fully explained by decreases in bone mineral density (BMD). We propose that this may be due to alterations in bone quality. Trabecular bone score (TBS) correlates with 3D bone micro-architectural parameters and can be derived directly from grey-level variations within 2D DXA images.<...

see PP209....

Obesity is associated with greater risk of proximal humerus and ankle fracture, despite greater areal BMD (aBMD). We aimed to investigate whether greater risk of some fractures in obesity was due to skeletal or non-skeletal determinants. 100 individually-matched pairs of normal weight (NW) (18.5–24.9 kg/m2) and obese (OB) (BMI >30 kg/m2) individuals, aged 25–40 and 55–75 years underwent DXA to determine hip and lumbar spine aBMD, whole ...

Background: Risk of fracture in chronic kidney disease (CKD) population is high and it is associated with increased mortality. CKD affects bone quality through changes in bone turnover, microarchitecture, and mineralization. Secondary hyperparathyroidism has different effects on cortical and trabecular bone but dual-energy X-ray absorptiometry (DXA) is unable to effectively differentiate these bone compartments. High resolution peripheral quantitative computed tomography (HRpQ...

Teriparatide is an anabolic agent given to reduce fracture risk in osteoporosis; it increases BMD and bone turnover. For monitoring treatment efficacy, serum PINP shows the greatest increase and low variability; it has been proposed as a marker of individual treatment response. We aimed to evaluate the utility of PINP to monitor teriparatide treatment in clinical practice.We performed a retrospective evaluation of 91 patients treated with teriparatide si...

Background: The presence of vascular calcification (VC) is a predictive factor for the development of cardiovascular diseases, especially in the obese population. VC has also been inversely associated with bone mineral density (BMD) but the results have been inconsistent. The main aim of this study was to evaluate the associations between VC, obesity and volumetric BMD (vBMD).Methods: We studied 148 healthy men and women, aged 55–75 years, divided i...

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover. Bisphosphonates may reduce the population of osteoclast precursor cells (OPCs). Our aims were to investigate the effect of bisphosphonates on i) OPCs and ii) bone turnover in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mea...

Treatment of postmenopausal osteoporosis with bisphosphonates reduces bone resorption and formation. Sclerostin, an osteocyte regulator of bone formation may be involved in these changes. Some studies have reported an increase in sclerostin associated with bisphosphonate treatment while others have reported a decrease. The aims were to determine the effect of bisphosphonates on i) circulating sclerostin and ii) PINP in postmenopausal women with osteoporosis. We studied 92 post...